MERGER ALERT - CIT and BSTC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

NEW YORK, NY / ACCESSWIRE / October 21, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:

Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.

CIT Group Inc. CIT
Agreement Announcement: October 16, 2020
Transaction Details: Under the terms of the merger, CIT Group stockholders will receive 0.0620 shares of First Citizens class A common stock for each share of CIT Group common stock they own.

To learn more about the CIT action and your rights, go to:

https://www.zlk.com/mna2/cit-group-inc-information-request-form

BioSpecifics Technologies Corp. BSTC
Merger Announcement: October 19, 2020
Transaction Details: Under the terms of the deal, Endo will commence an all-cash tender offer for all outstanding shares of BioSpecifics common stock at a price of $88.50 per share.

To learn more about the BSTC investigation and your rights, go to:
https://www.zlk.com/mna2/biospecifics-technologies-corp-information-request-form

Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
jlevi@levikorsinsky.com
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP